Softwr

Healthcare · head to head

Clue vs Therapixel

Clue logo

Clue

Healthcare

Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement

From
Free
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Clue has a free tier, so it costs nothing to try first.
  • Each has a real cost: Clue clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Clue covers Cycle and symptom tracking, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Clue and Therapixel actually diverge.

Attributes where Clue and Therapixel differ
AttributeClueTherapixel
Starting priceFreeOn request
Pricing modelFree with a Plus subscriptionquote
Free tierYesNo
PlatformsiOS, AndroidWeb

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Clue

  • Cycle and symptom tracking
  • Cycle insights and patterns
  • Research partnerships
  • EU-based data hosting
  • Fertility and conception mode
  • Perimenopause and other life stage tracking

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Clue

  • Someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given Clues EU basis and published stance on law enforcement requestsnot Therapixel
  • A user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community contentnot Therapixel
  • A buyer comparing Clue directly against Flo on current published privacy policy language before choosing which app to trustnot Therapixel
  • Someone tracking perimenopause or other non-standard cycle stages that some period apps do not support wellnot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Clue
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Clue
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Clue
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Clue

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Clue

  • Clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • Deeper cycle insights and predictions, the features most likely to justify tracking in the first place, are gated behind the Clue Plus subscription rather than fully free.
  • Being a smaller company than some competitors, Clue has less capital and legal resource to contest large-scale legal requests than a larger, better-funded rival might, despite its stated intent to do so.
  • Research partnerships using anonymised user data, while opt-in, still mean user-derived data can be used in ways beyond direct app functionality, and users should check current consent settings.
  • Cycle predictions rely on self-reported data and general population models, so accuracy for irregular cycles or specific medical conditions remains limited regardless of which app is used.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Clue

Free
  • Clue Plus$9.99/month
    • Free tier covers core cycle tracking, logging and basic predictions
    • Clue Plus adds deeper cycle insights, extended predictions and personalised content
    • Annual Plus plans typically offered at a lower effective monthly rate

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Clue if

  • You need cycle and symptom tracking.
  • You want to start without paying.
  • You work on iOS, Android.
  • You also want cycle insights and patterns.
Clue review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is Clue or Therapixel better?
Neither clearly leads. Clue starts at Free and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Clue or Therapixel?
Clue has a free tier; the other does not. Paid plans start at Free for Clue and On request for Therapixel.
Does Clue or Therapixel run on more platforms?
Clue runs on iOS, Android. Therapixel runs on Web.
Can I use Clue for free?
Yes. Clue has a free tier, so you can try it without paying. Therapixel starts at On request.
What is Clue best used for?
Clue is most often used for someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests, a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content, a buyer comparing clue directly against flo on current published privacy policy language before choosing which app to trust, someone tracking perimenopause or other non-standard cycle stages that some period apps do not support well. Of those, someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests and a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content are not what Therapixel is typically brought in for.
What can Clue do that Therapixel cannot?
Clue covers Cycle and symptom tracking, Cycle insights and patterns, Research partnerships, EU-based data hosting. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Clue: Does Clue share data with law enforcement?

Clue publishes a policy stating it does not share health data with law enforcement or public authorities without a legally binding request and states it will challenge requests it considers improper. This is the companys stated position; verify the current policy directly for specifics.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Clue: Why does Clue emphasise being an EU company?

Clue operates under EU GDPR data protection rules and states this legal basis makes it harder for authorities outside the EU, including US authorities, to compel data disclosure than for a company based in the US.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Clue: Is Clue free?

Core cycle tracking, logging and basic predictions are free. Deeper insights and extended predictions require Clue Plus.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on Clue

More on Therapixel

Keep looking

Other head to heads